Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront

GSK will spend $110 million upfront for a license to a KRAS-EGFR antibody conjugate developed by Hutchmed, with up to $1.185 billion in biobucks on the line. The Chinese biopharma said ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 3 September →